<DOC>
	<DOCNO>NCT02486068</DOCNO>
	<brief_summary>The primary objective trial : In patient high-risk restenosis , - To assess non-inferiority everolimus-eluting bioresorbable scaffold ( BRS ) everolimus elute cobalt chromium metallic stent ( EES ) target lesion failure ( TLF ) 1 year - To assess superiority BRS EES TLF 1 5 year</brief_summary>
	<brief_title>ABSORB Bioresorbable Scaffold vs. Xience Metallic Stent Prevention Restenosis Patients High Risk Restenosis</brief_title>
	<detailed_description />
	<criteria>Patients ( 1880 year old ) least one following : Highrisk characteristic restenosis Known Diabetes Multivessel disease one denovo target lesion treat study scaffold/stent Complex target lesion Single denovo target lesion satisfy least one following : Lesion length &gt; 28 mm Target lesion reference vessel diameter 2.252.75 mm Lesion preexist total occlusion ( preprocedural TIMI = 0 ) Bifurcation single stent strategy Patients exclude study : Age &lt; 18 year &gt; 80 year Renal insufficiency ( GFR/MDRD &lt; 45 ml/min ) Known comorbidities make patient unable complete 5year followup Known nonadherence DAPT Patients oral anticoagulation Cardiogenic Shock ( Killip &gt; 2 ) LVEF &lt; 30 % Following lesion characteristic : Target lesion reference vessel diameter ( RVD ) &lt; 2.25 &gt; 4 mm STEMI RVD &gt; 3.5mm culprit target lesion Target lesion instent/scaffold thrombosis Graft lesion target lesion Aortoostial lesion ( ) Left main lesion Severe tortuosity target vessel Inscaffold restenosis Bifurcation target lesion intend 2 stent/scaffold strategy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>